AstraZeneca awarded damages in Prilosec® patent litigation

Tuesday, 3 December 2013

AstraZeneca today announced a ruling by the US District Court for the Southern District of New York which ordered Apotex Corp., Apotex, Inc and Torpharm, Inc. (“Apotex”) to pay AstraZeneca approximately $76 million in damages. This ruling is a result of Apotex’s infringing sales of generic omeprazole between 2004 and 2007. This follows a previous ruling in 2007 that found two Prilosec® (omeprazole) formulation patents valid and infringed by Apotex.

AstraZeneca welcomes the court’s ruling.

These damages will not impact Core earnings or AstraZeneca’s full year 2013 financial guidance.


About the litigation

In June of 2007, Judge Barbara S. Jones of the United States District Court for the Southern District of New York upheld two of AstraZeneca’s formulation patents covering Prilosec®, a ruling consistent with her earlier decision related to the same patents in October 2002. The Court found that Apotex’s generic omeprazole formulation infringed both patents in suit.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit:


Media Enquiries    
Esra Erkal-Paler (UK/Global) +44 20 7604 8030
Ayesha Bharmal (UK/Global) +44 20 7604 8034
Michele Meixell
(US) +1 302 885 2677
Jacob Lund (Sweden) +46 8 553 260 20


Investor Enquiries      
Karl Hård +44 20 7604 8123 mob: +44 7789 654364
Colleen Proctor +1 302 886 1842 mob: +1 302 357 4882
Anthony Brown +44 20 7604 8067 mob: +44 7585 404943
Jens Lindberg +44 20 7604 8414 mob: +44 7557 319729